Pharmacologic Treatment of Osteoporosis
Osteoporosis is silent until fracture, so treatment aims to reduce fracture risk by either suppressing bone resorption (antiresorptive agents) or stimulating bone formation (anabolic agents). The framework divides therapy into antiresorptive drugs (oral and IV bisphosphonates, and the RANKL inhibitor denosumab) and anabolic drugs (PTH analogs and the sclerostin inhibitor romosozumab). Choice depends on severity, tolerance of oral therapy, and specific agent-related cautions.
Oral Bisphosphonates (Alendronate, Risedronate)
Alendronate and risedronate inhibit osteoclasts and are the first-line, workhorse agents for osteoporosis. They come in several oral formulations — daily and weekly for both agents, with risedronate also available monthly — and the less frequent regimens are commonly chosen for convenience and adherence. Administration counseling is high-yield regardless of dosing interval: take on an empty stomach with plain water and remain upright for at least 30 minutes to minimize esophageal irritation. Bisphosphonates are used for chronic management, not acute conditions.
IV Bisphosphonate (Zoledronic Acid)
Zoledronic acid is an osteoclast inhibitor given intravenously once yearly, making it the go-to bisphosphonate when oral agents are not tolerated or when adherence is a concern. A flu-like (acute-phase) reaction commonly follows the first dose. Beyond osteoporosis, zoledronic acid is the preferred bisphosphonate for hypercalcemia of malignancy (given with IV saline) and for Paget's disease of bone.
Denosumab (RANKL Inhibitor)
Denosumab is a monoclonal antibody against RANKL that prevents osteoclast formation, function, and survival. It is administered subcutaneously every 6 months. A critical exam point is rebound bone loss (with risk of multiple vertebral fractures) if the drug is stopped — patients should not simply discontinue therapy without transitioning to another antiresorptive agent.
Anabolic PTH Analogs (Teriparatide, Abaloparatide)
Teriparatide (PTH 1-34) and abaloparatide (a PTHrP analog) are anabolic agents that, when given intermittently, stimulate osteoblasts to build new bone. They are given as daily subcutaneous injections and reserved for severe osteoporosis or those at very high fracture risk. Use is limited to 2 years.
Romosozumab (Sclerostin Inhibitor)
Romosozumab is a monoclonal antibody against sclerostin with a unique dual action: it increases bone formation while simultaneously decreasing resorption. It is given subcutaneously monthly for 12 months and carries a cardiovascular warning.
High-yield
- Osteoporosis is silent until fracture — screen appropriately and treat with bisphosphonates, or anabolic agents for severe disease.
- Bisphosphonates (alendronate, risedronate, zoledronic acid) all work by inhibiting osteoclasts.
- Oral bisphosphonates come in daily, weekly, and (risedronate) monthly formulations; less frequent dosing aids adherence.
- Oral bisphosphonate rule: empty stomach, plain water, stay upright at least 30 minutes.
- Zoledronic acid = IV, yearly; use when oral bisphosphonates aren't tolerated; expect a flu-like reaction after the first dose.
- Denosumab = RANKL inhibitor (monoclonal antibody), SC every 6 months, prevents osteoclast formation.
- Teriparatide and abaloparatide are anabolic PTH/PTHrP analogs — daily SC, 2-year limit, for severe osteoporosis.
- Romosozumab = sclerostin inhibitor with dual anabolic + antiresorptive action, SC monthly × 12.
- Zoledronic acid is also preferred for Paget's disease of bone and hypercalcemia of malignancy.
Pitfalls
- Do not assume weekly is the only oral bisphosphonate schedule — daily, weekly, and monthly (risedronate) formulations exist.
- Do not use oral bisphosphonates for acute hypercalcemia emergencies — they are for chronic conditions; IV zoledronic acid with saline is used for hypercalcemia of malignancy.
- Stopping denosumab abruptly causes rebound bone loss and vertebral fractures — always transition to another antiresorptive rather than freely discontinuing.
- Confusing mechanisms: bisphosphonates directly inhibit osteoclasts, denosumab blocks RANKL to prevent osteoclast formation, while teriparatide/abaloparatide and romosozumab are anabolic.
- Forgetting the 2-year limit on PTH analog therapy.
- Overlooking the first-dose flu-like reaction associated with IV zoledronic acid.
- Neglecting oral bisphosphonate administration instructions, which are frequently tested and reduce esophageal injury.
Clinical pearls
- The first branch point in osteoporosis therapy is antiresorptive vs. anabolic.
- Anabolic agents (teriparatide, abaloparatide, romosozumab) are reserved for severe disease.
- Romosozumab uniquely both builds bone and blocks its breakdown.
- When a patient can't tolerate an oral bisphosphonate, switch to yearly IV zoledronic acid.
- Teriparatide/abaloparatide stimulate osteoblasts; bisphosphonates and denosumab shut down osteoclasts.
Frequently asked
How are oral bisphosphonates dosed?
Alendronate and risedronate are available in daily and weekly formulations, and risedronate also has a monthly option. Less frequent regimens are popular for improving adherence, but administration counseling (empty stomach, plain water, stay upright ≥30 minutes) applies to all schedules.
Why must patients stay upright for 30 minutes after taking oral bisphosphonates?
To minimize esophageal irritation. Alendronate and risedronate should be taken on an empty stomach with plain water while remaining upright for at least 30 minutes.
When is zoledronic acid preferred over oral bisphosphonates?
When oral bisphosphonates are not tolerated or adherence is a concern. Zoledronic acid is given IV once yearly, though a flu-like reaction commonly occurs after the first dose.
What is the key danger of stopping denosumab?
Rebound bone loss with risk of multiple vertebral fractures. Denosumab is a RANKL inhibitor given SC every 6 months, and discontinuation without transitioning to another antiresorptive leads to rapid bone loss.
Which osteoporosis drugs are anabolic rather than antiresorptive?
Teriparatide and abaloparatide (PTH/PTHrP analogs that stimulate osteoblasts) and romosozumab (a sclerostin inhibitor with dual formation-increasing and resorption-decreasing action).
How do the mechanisms of bisphosphonates and denosumab differ?
Bisphosphonates directly inhibit osteoclasts, while denosumab is a monoclonal antibody that inhibits RANKL, preventing osteoclast formation.
What limits the use of teriparatide and abaloparatide?
They are reserved for severe osteoporosis, given as daily SC injections, and are limited to 2 years of use.
In severe hypercalcemia of malignancy, why is IV zoledronic acid used instead of an oral bisphosphonate?
Oral bisphosphonates are for chronic conditions, not emergencies. IV zoledronic acid (with IV saline) inhibits osteoclasts but takes 2–4 days to work, so calcitonin can be used as a rapid bridge.
Turn this into reasoning you can use on exam day — practice Pharmacologic Treatment of Osteoporosis on branching cases where your decisions shape the patient.